Diabetes Therapies & Diagnostics: Global Markets

Published - Jun 2010| Analyst - Paul Evers| Code - HLC029C
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

  • The global market for therapeutic and diagnostic products for diabetes is valued at $38 billion in 2010. This market is expected to grow at a compound annual growth rate (CAGR) of 6.1% to reach $51.2 billion in 2015.
  • Insulin products, including administration devices, are worth an estimated $16.4 billion in 2010. This sector is expected to reach $22 billion in 2015, a 6.1% compound annual growth rate (CAGR). 
  • Oral hypoglycemic drugs are expected to achieve the highestcompound annual growth rate (CAGR) of 8%, increasing from $10.3 billion in 2010 to $15.1 billion in 2015.


The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for prescription generic drugs used in the treatment of diabetes and devices and instruments used for diagnosis and monitoring of diabetes. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2015; these are based on epidemiological data and projections, plus information on R&D trends and differential market potential on a country-by-country basis. Healthcare policies, demographics, and the wider economic environment are also taken into account.
It is widely recognized that the prevalence of the commonest type of diabetes mellitus, Type 2, is now reaching epidemic proportions all over the world. Cases of Type 1 DM are also on the increase, although to a less spectacular degree. These trends are of great concern, not only to the individuals concerned, but to governments and providers of healthcare, because the economic consequences of diabetes are vast, as they involve not only the direct burden of managing the disease but also the common and often catastrophic complications including cardiovascular disease, peripheral neuropathy and blindness.
Thus the prompt diagnosis and effective treatment of diabetes are essential, not optional, priorities for governments and healthcare agencies. One consequence is that the already large market for diabetes monitoring and treatment will certainly grow in line with increasing incidence and with improvements in diagnosis. Thus diabetes is of great commercial significance to the suppliers of drugs used in treatment and devices needed for monitoring.
Among the information needs of companies in this field is accurate and up-to-date assessment of the current extent of the diabetes epidemic, its likely evolution over the next 5 years, and the impact of drugs and technical developments now in the pipeline.
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, both in global terms and analyzed by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for main drug and device categories, and breakdowns are provided for several national markets.
Market figures are based on revenues at the manufacturer level and are projected at 2010-dollar value without attempting to predict the effect of inflation/deflation.
Therapeutic categories quantified and forecast include insulins and oral hypoglycemic agents, and devices including blood glucose monitors and accessories.
Primary research includes interviews with leading individuals in relevant companies and medical associations; primary sources of published data include epidemiological and economic studies, company annual reports, SEC filings, and government publications. Secondary sources consist of literature searches, industry journals, and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically assessed by BCC.
This report is designed to satisfy the information needs of a wide variety of individuals involved in the diabetes marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning, and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.
Sources of information included marketing strategists, industry executives, government and professional agencies, and surveys of physicians. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also mined, as well as publications of relevant associations such as the International Diabetes Federation and the American and British Diabetic Associations.
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the diabetes marketplace covering both therapeutic and monitoring aspects. 
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:  
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
Published - Mar-2008| Analyst - Ann Zhai| Code - HLC029B

Report Highlights

  • The global market for diabetes therapeutics and diagnostics increased from $208.5 billion in 2007 to an estimated $213.8 billion by the end of 2008. It should reach $241.9 billion by 2013, a compound annual growth rate (CAGR) of 2.5%.
  • The global diabetes market will become one of the largest healthcare markets over the next five years, due in large part to the epidemic explosion of the type II diabetes population.
  • Over the next five years, market leaders will overcome technology barriers to bring non-invasive, insulin-dependent products to the market.
Published - Oct-2002| Analyst - Amy Adams| Code - HLC029A

Report Highlights

  • The total market for diabetes drugs and devices is estimated at $18 billion in 2002. Growing at an average annual rate (AAGR) of 11.5%, the market is expected to exceed $30.7 billion in 2007.
  • Drug sales in 2002 are expected to be $12.5 billion, increasing to almost $21 billion by 2007 at an AAGR of 10.3%.
  • Insulin was 33% of the market in 2000 and is expected to hold on to that share.
  • Sulfanylureas and biguanides are expected to lose considerable market share to generics, newer classes of drugs, and to the extremely popular thiazolidinediones.
  • The two major diabetes medical devices are glucose monitors and insulin pumps. Glucose monitors are expected to rise at an AAGR of 13.7% to $8 billion by 2007. Insulin pumps are expected to grow to $1.8 billion by 2007 at an AAGR of 18.7%.


Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report